ZAI LAB (09688.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec23

ZailABS COBENFY® Approved by China's National Medical Products Administration

12:30

Dec22

UBS Gives Anzhi Medicine a Buy Rating

02:30

Dec18

Zai Lab Ltd. Chief Legal Officer Reports Common Stock Disposition

21:35

Dec8

Zailabor Begins First-In-Human Phase 1/1B Study for ZL-1503

12:26

Nov25

Zai Lab's Chief Legal Officer Sells Company Common Stock

21:12

Nov11

UBS Maintains Buy Rating on Zai Lab Ltd With Price Target

00:36

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 903.53 M, Net Income -279.89 M, EPS -0.2539

Zai Lab Limited (ZLAB.US/09688.HK) Q3 2025 Earnings Conference Call

Aug7

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 863.31 M, Net Income -319.7 M, EPS -0.2927

May8

Earning Release(CST)

FY2025 Q1 Earning Release (HKD) Revenue 828.4 M, Net Income -376.82 M, EPS -0.3486

Zai Lab Limited (ZLAB.US/09688.HK) Q1 2025 Earnings Conference Call

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change